Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Santen’s Glaucoma Med Rhopressa Hits Shelves in South Korea
November 5, 2024
- Mitsubishi to Take Another Stab at Parkinson’s Drug Submission in US
November 5, 2024
- LEO Pharma, Kyowa Kirin to Wind Up Dovobet Collaboration
November 5, 2024
- FDA Rolling Submission for Leqembi SC Completed: Eisai
November 5, 2024
- Takeda’s Japan Sales Ratio Falls Below 10%, Global Biz Thrives in H1
November 1, 2024
- Daiichi Sankyo Ups Outlook on Earnings Growth Driven by Enhertu
November 1, 2024
- Ono President Hopes to Turn Deciphera into Black in 2-3 Years
November 1, 2024
- Daiichi Sankyo Starts 3 Global PIII Trials of TROP2 ADC for NSCLC
November 1, 2024
- Kyowa Kirin Picks Abdul Mullick as New President and COO
November 1, 2024
- Otsuka Holdings Names Makoto Inoue as New CEO
November 1, 2024
- Ono’s H1 Revenue Falters 7% after Opdivo Price Cuts
November 1, 2024
- Mochida Bags Japan Rights to United Therapeutics’ Tyvaso DPI
November 1, 2024
- Tecentriq Filed for Rare Nasal Lymphoma in Japan: Chugai
November 1, 2024
- Astellas Records 22% Revenue Growth in 1H Riding on Strategic Assets
October 31, 2024
- Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring
October 31, 2024
- iPark to Hold 1st US Investor Confab to Woo VCs for Asian Startups
October 31, 2024
- Orion Japan to Take Back Parkinson’s Drugs from Novartis
October 31, 2024
- Leqembi’s July-September Sales Up 1.6-Fold QOQ: Eisai
October 31, 2024
- 604 Employees Raise Hands for Sumitomo’s Buyout Program
October 31, 2024
- Sumitomo Sales Surge 18% in April-September on 3 Key Brands
October 31, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…